08158 CRMI
- 0.162
- +0.015+10.20%
CRMI News
中國再生醫學：年報2023
China Regenerative Medicine (08158.HK): Shareholders' share loss of approximately HK$108 million in 2023
On April 2, China Regenerative Medicine (08158.HK) announced that for the year ended December 31, 2023, revenue was approximately HK$69.49 million, an increase of 67.29% over the previous year; gross profit decreased by 48.37% from the previous year to approximately HK$19.42 million; the company's equity holders should account for the current year's loss of approximately HK$108 million (2022: profit of HK$4.56 million), with a basic loss of HK$37.60 per share.
CRMI: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
China Regenerative Medicine (08158.HK) appoints Zhongzheng Tianheng as new auditor
Gelonghui, January 25 | China Regenerative Medicine (08158.HK) announced that Changying (Hong Kong) Certified Public Accountants Limited (“Changying”) submitted a letter of resignation to the board of directors to resign as the company's auditor with immediate effect. Following the recommendation of the Audit Committee, it has decided to appoint Zhongzheng Tianheng Certified Public Accountants Co., Ltd. (“Zhongzheng Tianheng”) as the company's new auditor.
China Regenerative Medicine (08158) affiliate plans to inject 10.25 million yuan into Changzhou Pomei Biotechnology
Zhitong Finance App News, China Regenerative Medicine (08158) announced that on December 29, 2023 (after the transaction period), China Regenerative Health, Changzhou Starry Sky, and the target company Changzhou Bomei Biotechnology Co., Ltd. signed a capital increase and subscription agreement. According to this, China Regenerative Health must inject RMB 10.25 million into the target company in cash, of which RMB 250,000 will be injected to increase the target company's registered capital, while RMB 10 million will be injected into its capital reserve. Upon completion, the target company will hold approximately 33.3% of China Regenerative Health's equity and Changzhou Star
CRMI: THIRD QUARTERLY RESULTS ANNOUNCEMENT FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2023
CRMI: Third Quarterly Report 2023
China Regenerative Medicine (08158) released its first three quarter results, net profit of HK$6.677 million, down 36.7% year on year
China Regenerative Medicine (08158) announced the results for the nine months ended September 30, 2023, with revenue of 112 million...
CRMI: THIRD QUARTERLY RESULTS ANNOUNCEMENT FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2023
China Regenerative Medicine (08158) announced interim results; net profit of HK$127.62 million increased 4.74 times year-on-year
According to the Zhitong Finance App, China Regenerative Medicine (08158) announced its 2023 interim results, with revenue of about HK$100 million, an increase of 16.04%; net profit of HK$12.762 million, an increase of 4.74 times over the previous year; profit of HK0.447 cents per share.
CRMI: Interim Report 2023
CRMI: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2023
CRMI To Carry Out 1-for-10 Reverse Stock Split On September 6th, 2023
August 5th - $CRMI(08158.HK)$ is about to implement a 1-for-10 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from September 6th, 2023.$CRMI(08158.HK)$ slipped
CRMI: NOTICE OF BOARD MEETING
China Regenerative Medicine (08158) plans to restructure its share capital
According to the Zhitong Finance App, China Regenerative Medicine (08158) issued an announcement. The board of directors proposed implementing a share merger. The benchmark is to merge every 10 issued and unissued existing shares into 1 consolidated share. A share merger must wait (including) the shareholders to approve an ordinary resolution at the Extraordinary General Meeting of Shareholders before being effective. The Board of Directors recommended implementing a reduction in share capital immediately following the entry into force of the share merger. The cancellation of any fragmented consolidated shares of the company's issued share capital resulting from the share merger and the company's issued share capital will be reduced through cancellation of the full paid share capital (up to the cancellation of HK$1.80 for each consolidated share issued at the time).
China Regenerative Medicine (08158.HK) achieved revenue of HK$54.1 million in the first quarter
Glonghui, May 16 丨 China Regenerative Medicine (08158.HK) announced that in the first quarter of 2023, the Group's revenue during the period was approximately HK$54.1 million, an increase of about 4% over the previous year. The overall increase in revenue was mainly due to increased revenue from the Big Health Products and Services segment. The Group recorded gross profit of about HK$10 million during the period, an increase of about 7% over the previous year. Gross margin increased from 12% in the previous period to 19% during the period, as the Group provided services with higher gross profit to customers.
CRMI: FIRST QUARTERLY RESULTS ANNOUNCEMENT FOR THE THREE MONTHS ENDED 31 MARCH 2023
CRMI: First Quarterly Report 2023
Avaya Named for Excellence in Customer Service With a NorthFace ScoreBoard Service Award (NFSB) for the 10th Consecutive Year by the Customer Relationship Management Institute (CRMI)
Support Services Teams Achieved a Perfect Customer Satisfaction (CSAT) Score in Field Technical Support and a 97% CSAT Score for Remote SupportMORRISTOWN, N.J.--(BUSINESS WIRE)--Avaya, a global leader
Regenerative Medicine in China: Clarification Notice
Analysis
Price Target
No Data
